WO2002046751A3 - Methods of predicting chemotherapy response - Google Patents

Methods of predicting chemotherapy response Download PDF

Info

Publication number
WO2002046751A3
WO2002046751A3 PCT/US2001/051196 US0151196W WO0246751A3 WO 2002046751 A3 WO2002046751 A3 WO 2002046751A3 US 0151196 W US0151196 W US 0151196W WO 0246751 A3 WO0246751 A3 WO 0246751A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
predicting
patient
chemotherapy response
chemotherapy
Prior art date
Application number
PCT/US2001/051196
Other languages
French (fr)
Other versions
WO2002046751A2 (en
WO2002046751A9 (en
Inventor
Vladimir D Kravtsov
Mark J Koury
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Priority to AU2002241791A priority Critical patent/AU2002241791A1/en
Publication of WO2002046751A2 publication Critical patent/WO2002046751A2/en
Publication of WO2002046751A9 publication Critical patent/WO2002046751A9/en
Publication of WO2002046751A3 publication Critical patent/WO2002046751A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of predicting the effect of chemotherapy on a patient is disclosed. In this method, the patient is suffering form a disease or condition that can be treated or prevented by the administration to the patient of a drug which acts by inducing apoptosis. A method of predicting the effect of chemotherapy on the survival rate of a patient population suffering from a disease or condition that can be treated by chemotherapy is also disclosed.
PCT/US2001/051196 2000-11-13 2001-11-13 Methods of predicting chemotherapy response WO2002046751A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002241791A AU2002241791A1 (en) 2000-11-13 2001-11-13 Methods of predicting chemotherapy response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24705300P 2000-11-13 2000-11-13
US60/247,053 2000-11-13

Publications (3)

Publication Number Publication Date
WO2002046751A2 WO2002046751A2 (en) 2002-06-13
WO2002046751A9 WO2002046751A9 (en) 2002-12-27
WO2002046751A3 true WO2002046751A3 (en) 2004-01-08

Family

ID=22933356

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/051191 WO2002046750A2 (en) 2000-11-13 2001-11-12 Methods of predicting chemotherapy response
PCT/US2001/051196 WO2002046751A2 (en) 2000-11-13 2001-11-13 Methods of predicting chemotherapy response

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051191 WO2002046750A2 (en) 2000-11-13 2001-11-12 Methods of predicting chemotherapy response

Country Status (2)

Country Link
AU (2) AU2002239771A1 (en)
WO (2) WO2002046750A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053704A1 (en) * 2003-12-01 2005-06-16 Novartis Ag Method for predicting drug responsiveness in myeloid neoplasms
BRPI1012980A2 (en) * 2009-05-19 2016-03-29 Vivia Biotech Sl device and methods for analyzing cellular responsiveness and neoplastic cell response to drugs
BR112012024619A2 (en) * 2010-03-31 2016-05-31 Diatech Oncology Llc system and method for evaluating anticancer drug candidate
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
US6258553B1 (en) * 1996-11-14 2001-07-10 Vanderbilt University Assay for measuring apoptosis in cell culture

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAVTSOV V D ET AL: "Prediction of survival and responses to chemotherapy in acute myelogenous leukemia (AML) by the microculture kinetic (MiCK) assay of apoptosis.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 677A, XP001107076, ISSN: 0006-4971 *
KRAVTSOV VALDIMIR D ET AL: "Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.", BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 968 - 980, XP002118802, ISSN: 0006-4971 *
KRAVTSOV VLADIMIR D ET AL: "Chemotherapy of myeloid leukemia directed by a microculture kinetic (MiCK) assay for apoptosis.", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 724a, XP001106433, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2002046750A3 (en) 2003-02-13
AU2002241791A1 (en) 2002-06-18
WO2002046751A2 (en) 2002-06-13
WO2002046751A9 (en) 2002-12-27
WO2002046750A2 (en) 2002-06-13
AU2002239771A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
WO2004014953A3 (en) Anti-myelin associated glycoprotein (mag) antibodies
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2002003915A3 (en) Methods of producing weight loss and treatment of obesity
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005046603A3 (en) Pyridine compounds
WO2005082382A8 (en) Formulations of thiomolybdate or thiotungstate compounds and uses thereof
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
NO20054913L (en) Use of clustein for the treatment and / or prevention of peripheral neurological disorders
WO2001098279A3 (en) Bis-arylsulfones
WO2004112718A3 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
MXPA05012358A (en) Pharmaceutical combination comprising modafinil and another drug.
WO2004066983A3 (en) Controlled release of highly soluble agents
MXPA04003717A (en) Chewable tablet containing lysine.
WO2002046751A3 (en) Methods of predicting chemotherapy response
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2000061231A3 (en) Medical use
WO2005004806A3 (en) Combination therapy for treating chronic inflammatory diseases
IL154419A0 (en) The treatment of inflammatory disorders
WO2001078720A8 (en) Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
WO2002092064A3 (en) Therapeutic method for inducing tolerance
WO2005107464A3 (en) Compounds and compositions as cathepsin s inhibitors
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP